Figure 4. Treatment with erastin and RSL3 delays prostate cancer growth in vivo.

(A) Schematic diagram of experimental design using erastin treatment. 5×10⁵ DU145, ARCaP or PC3 (5×10⁵) and NCI-H660 (1×10⁶) cells were mixed in 50 μl of 80% matrigel and implanted subcutaneously (sc) into the flanks of male NSG mice. When tumors averaged 50 to 80 mm³, mice were randomized into vehicle or erastin treatment (20 mg/kg, IP, daily) groups. (B) DU145, ARCaP, PC3, and H660 tumors volumes were measured by caliper (1/2 × (Length × Width × Height)) every three days and presented as fold change over the tumor volume at Day 1. (C) Tumor weights (g) were measured following tumor excision at the experimental end point and graphed as violin plots. (D) Schematic diagram of experimental design upon RSL3 treatment. (E) DU145 and PC3 (5×10⁵) cells were mixed in 80% Matrigel and implanted subcutaneously into flank of NSG male mice. Once the average of tumor volume reached to 50 to 80 mm³, mice were randomized into vehicle or RSL3 treatment (100 mg/kg, IP, biweekly) groups. Tumor volumes (1/2 (Length × Width × Height)) were measured every third day and shown as fold change over Day 1 tumor volume. (F) Tumor weights (g) were measured at the experimental end point. Statistical analysis was performed with Student’s t-test at each time point (* P<0.05, **P<0.01, *** P<0.001, and **** P<0.0001). Error bars signify mean ± SEM.